ELIZABETH HARGIS: Open Payments
NPI 1063933877 · LOUISVILLE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,056 in 112 payments from 15 companies in 2025. Trend: 2023 $2,198 · 2024 $2,004 · 2025 $2,056
Food & beverage: $2,022Education: $34
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 26 | $547 |
| CSL Behring | 12 | $249 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $246 |
| GlaxoSmithKline, LLC. | 16 | $237 |
| Amgen Inc. | 15 | $237 |
| Regeneron Healthcare Solutions, Inc. | 12 | $173 |
| Novartis Pharmaceuticals Corporation | 7 | $156 |
| GENZYME CORPORATION | 3 | $64 |
| Genentech USA, Inc. | 2 | $31 |
| Hikma Pharmaceuticals USA | 1 | $21 |
Products named: TEZSPIRE, FASENRA, DUPIXENT, NUCALA, Hizentra, CUVITRU, AIRSUPRA, Rhapsido.
Industry payments across KY — which companies pay providers there.
